MetrioPharm receives EU grant for Covid-19 project

28 July 2021 11:44

Supporting partner

Zurich – MetrioPharm AG has developed a potential coronavirus treatment which it is testing together with partners. The European Commission is now supporting the research project through a funding program launched as part of its pandemic response.

The lead compound MP1032 from Zurich company MetrioPharm could be a promising option for coronavirus treatment in future. The drug has demonstrated strong immunomodulatory and specific antiviral properties against SARS-CoV-2 in preclinical studies. It is currently being tested in a large-scale research project with three partner companies, namely CatalyzeMC Toxicology Consulting and ImmunoLogik.

The European Commission now intends to support this research project through funding under its HERA Incubator, as was reported in a press release. This funding program was launched in April 2021 to combat the coronavirus and its variants. MetrioPharm’s iMPact project is one of 11 initiatives selected for the program.

“We are very pleased with the announcement by the European Commission and the vote of confidence in our compound MP1032,” said MetrioPharm CEO Wolfgang Brysch in the press release. The decision is rated as support for the pharmaceutical development steps already taken and going forward for MP1032 in countering Covid-19. 

Swiss Pavilion Digital